Sign In
Buy SGPYY
$42.52
+0.0600 (+0.141%)
At Close: Jun 23, 2026
Sage Potash Obtains Approval for US$14 Million USDA Grant to Advance Project
03:05am, Tuesday, 02'nd Sep 2025
Significant progress on technical studies, permitting and engineering Vancouver, British Columbia--(Newsfile Corp. - September 2, 2025) - Sage Potash Corp. (TSXV: SAGE) (OTCQB: SGPTF) ("Sage Potash" o
Sage Potash Grants Stock Options to the Honourable Stockwell Day
03:50pm, Wednesday, 27'th Aug 2025
Vancouver, British Columbia--(Newsfile Corp. - August 27, 2025) - Sage Potash Corp. (TSXV: SAGE) (OTCQB: SGPTF) ("Sage Potash" or the "Company"), a Canadian company focused on developing its Sage Plai
Sage Potash Announces That Stockwell Day Joins Its Board of Directors
08:30am, Thursday, 14'th Aug 2025
Vancouver, British Columbia--(Newsfile Corp. - August 14, 2025) - Sage Potash Corp. (TSXV: SAGE) (OTCQB: SGPTF) ("Sage Potash" or the "Company"), a Canadian company focused on developing its Sage Plai
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
08:44am, Thursday, 31'st Jul 2025
Acquisition strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform, accelerating mid-
The Sage Group plc (SGGEF) Presents at Sales/Trading Statement Conference Transcript
07:08am, Wednesday, 30'th Jul 2025
The Sage Group plc (OTCPK:SGGEF) Sales/Trading Statement Conference Call July 30, 2025 3:30 AM ET Company Participants Jonathan Anton George Howell - CFO & Director Conference Call Participants Adam D
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
08:25am, Monday, 28'th Jul 2025
ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) ("Supernus", and the "Company"), today announced that the required waiting perio
BEAUFORT, S.C.--(BUSINESS WIRE)-- #CVD--A new report published by THE SAGE GROUP quantifies CVD prevalence and incidence for the 2020-2040 period. “Chronic venous disease afflicts 1.5 times as many
Sage Potash Announces Director Resignation and Grant of Stock Options
03:30pm, Monday, 07'th Jul 2025
Vancouver, British Columbia--(Newsfile Corp. - July 7, 2025) - Sage Potash Corp. (TSXV: SAGE) (OTCQB: SGPTF) ("Sage Potash" or the "Company"), a Canadian company focused on developing its Sage Plain P
Sage Group: Slow burner, no fireworks, says leading investment bank
09:31am, Wednesday, 02'nd Jul 2025
JP Morgan's preview of The Sage Group PLC (LSE:SGE) third-quarter figures suggests there won't be fireworks when the software group reports on July 30. Analysts there reckon the company will deliver
Sage Potash Closes C$6 Million Private Placement
07:42pm, Thursday, 26'th Jun 2025
Vancouver, British Columbia--(Newsfile Corp. - June 26, 2025) - Sage Potash Corp. (TSXV: SAGE) (OTCQB: SGPTF) ("Sage Potash" or the "Company"), a Canadian company focused on developing its Sage Plain
Greenbriar Sustainable Living Inc. Highlights Progress on Water Rights for Sage Ranch and Discusses Tehachapi Water Market
05:55pm, Tuesday, 24'th Jun 2025
Scottsdale, Arizona--(Newsfile Corp. - June 24, 2025) - Greenbriar Sustainable Living Inc. (TSXV: GRB) (OTC Pink: GEBRF) ("Greenbriar" or the "Company") is pleased to share progress in securing water
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News
02:22pm, Tuesday, 17'th Jun 2025
Supernus Pharmaceuticals, Inc. SUPN on Monday agreed to acquire Sage Therapeutics, Inc. SAGE for $12.00 per share in cash, or an aggregate of up to approximately $795 million.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.
05:31pm, Monday, 16'th Jun 2025
NEW YORK , June 16, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Sage Therapeutics, Inc. (NASDAQ: SAGE) and its board of directors concerning the propos
Sage Therapeutics Stock Soars 35% After Sale to Supernus. What We Know.
07:42am, Monday, 16'th Jun 2025
The deal is worth an initial $561 million, with potential for $234 million in add-ons.
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Sage (NASDAQ: SAGE) for possible breaches of fiduciary duty and other violations of law in its transaction with Supernus Pharmaceuticals. Cl
